特发性肺纤维化的细胞疗法:当前进展与未来展望。

IF 1.5 Q4 CELL BIOLOGY
American journal of stem cells Pub Date : 2024-08-25 eCollection Date: 2024-01-01 DOI:10.62347/DAKS5508
Nicholas T Le, Matthew W Dunleavy, Rebecca D Kumar, William Zhou, Sumrithbir S Bhatia, Ahmed H El-Hashash
{"title":"特发性肺纤维化的细胞疗法:当前进展与未来展望。","authors":"Nicholas T Le, Matthew W Dunleavy, Rebecca D Kumar, William Zhou, Sumrithbir S Bhatia, Ahmed H El-Hashash","doi":"10.62347/DAKS5508","DOIUrl":null,"url":null,"abstract":"<p><p>Idiopathic pulmonary fibrosis (IPF) is an interstitial, fibrotic lung disease characterized by progressive damage. Lung tissues with IPF are replaced by fibrotic tissues with increased collagen deposition, modified extracellular matrix, all which overall damages the alveoli. These changes eventually impede the gas exchange function of the alveoli, and eventually leads to fatal respiratory failure of the lung. Investigations have been conducted to further understand IPF's pathogenesis, and significant progress in understanding its development has been made. Additionally, two therapeutic treatments, Nintedanib and Pirfenidone, have been approved and are currently used in medical applications. Moreover, cell-based treatments have recently come to the forefront of developing disease therapeutics and are the focus of many current studies. Furthermore, a sizable body of research encompassing basic, pre-clinical, and even clinical trials have all been amassed in recent years and hold a great potential for more widespread applications in patient care. Herein, this article reviews the progress in understanding the pathogenesis and pathophysiology of IPF. Additionally, different cell types used in IPF therapy were reviewed, including alveolar epithelial cells (AECs), circulating endothelial progenitors (EPCs), mixed lung epithelial cells, different types of stem cells, and endogenous lung tissue-specific stem cells. Finally, we discussed the contemporary trials that employ or explore cell-based therapy for IPF.</p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11411253/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects.\",\"authors\":\"Nicholas T Le, Matthew W Dunleavy, Rebecca D Kumar, William Zhou, Sumrithbir S Bhatia, Ahmed H El-Hashash\",\"doi\":\"10.62347/DAKS5508\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Idiopathic pulmonary fibrosis (IPF) is an interstitial, fibrotic lung disease characterized by progressive damage. Lung tissues with IPF are replaced by fibrotic tissues with increased collagen deposition, modified extracellular matrix, all which overall damages the alveoli. These changes eventually impede the gas exchange function of the alveoli, and eventually leads to fatal respiratory failure of the lung. Investigations have been conducted to further understand IPF's pathogenesis, and significant progress in understanding its development has been made. Additionally, two therapeutic treatments, Nintedanib and Pirfenidone, have been approved and are currently used in medical applications. Moreover, cell-based treatments have recently come to the forefront of developing disease therapeutics and are the focus of many current studies. Furthermore, a sizable body of research encompassing basic, pre-clinical, and even clinical trials have all been amassed in recent years and hold a great potential for more widespread applications in patient care. Herein, this article reviews the progress in understanding the pathogenesis and pathophysiology of IPF. Additionally, different cell types used in IPF therapy were reviewed, including alveolar epithelial cells (AECs), circulating endothelial progenitors (EPCs), mixed lung epithelial cells, different types of stem cells, and endogenous lung tissue-specific stem cells. Finally, we discussed the contemporary trials that employ or explore cell-based therapy for IPF.</p>\",\"PeriodicalId\":7657,\"journal\":{\"name\":\"American journal of stem cells\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11411253/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of stem cells\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62347/DAKS5508\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of stem cells","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/DAKS5508","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

特发性肺纤维化(IPF)是一种以进行性损伤为特征的间质性纤维化肺病。患 IPF 的肺组织会被纤维化组织取代,胶原沉积增加,细胞外基质发生改变,所有这些都会对肺泡造成整体损害。这些变化最终会阻碍肺泡的气体交换功能,最终导致致命的肺部呼吸衰竭。为了进一步了解 IPF 的发病机理,人们进行了大量研究,并在了解其发展方面取得了重大进展。此外,宁替达尼(Nintedanib)和吡非尼酮(Pirfenidone)这两种治疗方法已经获得批准,目前正在医疗应用中。此外,以细胞为基础的治疗方法最近已成为开发疾病疗法的前沿,也是当前许多研究的重点。此外,近年来还积累了大量的研究成果,包括基础研究、临床前研究、甚至临床试验,这些研究成果为在患者护理中更广泛的应用提供了巨大的潜力。本文回顾了人们在了解 IPF 发病机制和病理生理学方面取得的进展。此外,还回顾了用于治疗 IPF 的不同细胞类型,包括肺泡上皮细胞(AECs)、循环内皮祖细胞(EPCs)、混合肺上皮细胞、不同类型的干细胞和内源性肺组织特异性干细胞。最后,我们讨论了采用或探索细胞疗法治疗 IPF 的当代试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects.

Idiopathic pulmonary fibrosis (IPF) is an interstitial, fibrotic lung disease characterized by progressive damage. Lung tissues with IPF are replaced by fibrotic tissues with increased collagen deposition, modified extracellular matrix, all which overall damages the alveoli. These changes eventually impede the gas exchange function of the alveoli, and eventually leads to fatal respiratory failure of the lung. Investigations have been conducted to further understand IPF's pathogenesis, and significant progress in understanding its development has been made. Additionally, two therapeutic treatments, Nintedanib and Pirfenidone, have been approved and are currently used in medical applications. Moreover, cell-based treatments have recently come to the forefront of developing disease therapeutics and are the focus of many current studies. Furthermore, a sizable body of research encompassing basic, pre-clinical, and even clinical trials have all been amassed in recent years and hold a great potential for more widespread applications in patient care. Herein, this article reviews the progress in understanding the pathogenesis and pathophysiology of IPF. Additionally, different cell types used in IPF therapy were reviewed, including alveolar epithelial cells (AECs), circulating endothelial progenitors (EPCs), mixed lung epithelial cells, different types of stem cells, and endogenous lung tissue-specific stem cells. Finally, we discussed the contemporary trials that employ or explore cell-based therapy for IPF.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信